{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-002411","form_type":"8-K","ticker":"STIM","cik":"0001227636","company_name":"Neuronetics, Inc.","filed_at":"2024-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.607892+00:00","generated_at":"2026-06-05T03:26:42.065773+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Neuronetics Q4 revenue up 12% to $20.3M; net loss narrows to $5.4M; first positive cash flow","bullets":["Q4 2023 revenue $20.3M (+12% YoY); full-year revenue $71.3M (+9% YoY).","Q4 net loss $(5.4)M ($(0.19)/share) vs $(8.3)M loss a year ago; first-ever positive cash flow of $1.5M.","U.S. treatment session revenue up 20% in Q4 to $14.9M; local consumable treatment session revenue up >33%.","Full-year 2024 revenue guidance $78M-$80M; Q1 2024 guidance $16.7M-$17.7M.","Launched Better Me Guarantee Provider pilot with ~100 sites; insurers reduce TMS eligibility to 2 medication failures."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-002411","json":"https://secwatch.observer/filing/0001558370-24-002411.json","markdown":"https://secwatch.observer/filing/0001558370-24-002411.md","text":"https://secwatch.observer/filing/0001558370-24-002411.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1227636/000155837024002411/0001558370-24-002411-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1227636/000155837024002411/stim-20240305x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T03:26:42.065773+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5dd8b783746ca96c8ddbd628322591698bf7b1a3","claim":"Neuronetics, Inc. reported three and twelve months ended December 31, 2023 results: revenue $20.3 million; $71.3 million, net income $(5.4) million; not stated for full year, EPS $(0.19) per share; not stated for full year.","evidence_excerpt":"in the world, today announced its financial and operating results for the fourth quarter and full year of 2023. Fourth Quarter 2023 Highlights ● Fourth quarter 2023 revenue of $20.3 million, a 12% increase as compared to the fourth quarter 2022 ● U.S. NeuroStar Advanced Therapy system revenue of $4.5 million, in the quarter, the Company shipped 59 systems ● Achieved","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1227636/000155837024002411/0001558370-24-002411-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three and twelve months ended December 31, 2023"},{"label":"Revenue","value":"$20.3 million; $71.3 million"},{"label":"Net income","value":"$(5.4) million; not stated for full year"},{"label":"EPS","value":"$(0.19) per share; not stated for full year"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}